January 25, 2022
Lead-Related Venous Obstruction in Patients With Implanted Cardiac Devices: JACC Review Topic of the Week.
Key result
Anticoagulation remains the mainstay of treatment for cardiac implantable electronic device lead-associated venous obstruction, alongside thrombus debulking, lead extraction, venoplasty, and stenting.
Why the study?
Risk factors for cardiac implantable electronic device lead-associated venous obstruction remain poorly understood despite increasing device implantation rates and substantial associated symptoms.
Population
Patients with cardiac implantable electronic device lead-associated venous obstruction
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform CIED lead-related venous obstruction management; leaves open need for prospective trials to guide practice.
Structured PICO
P
Population
Patients with implanted cardiac devices experiencing lead-related venous obstruction (subclavian, brachiocephalic, or superior vena cava veins)
E
Exposure
Evaluation and management strategies including anticoagulation, thrombus debulking, lead extraction, venoplasty, and stenting
Provides a multidisciplinary framework for the evaluation and management of venous obstruction associated with cardiac implantable electronic device leads.
Cite This Study
Zimetbaum et al. (2022) conducted a review in Cardiac implantable electronic device lead-associated venous obstruction. Evaluation and management strategies (anticoagulation, thrombus debulking, lead extraction, venoplasty, stenting) was evaluated. Anticoagulation remains the mainstay of treatment for cardiac implantable electronic device lead-associated venous obstruction, alongside thrombus debulking, lead extraction, venoplasty, and stenting.